RFA-OD-20-020 - Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)
RFA-OD-20-021 - Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)
RFA-OD-20-016 - Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)
RFA-OD-20-023 - Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)
NOT-OD-20-159 - Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Wastewater Surveillance Research for Public Health Response to Coronavirus Disease 2019 (COVID-19)
NOT-OD-20-152 - Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool
NOT-OD-21-035 - Limited Competition for Emergency Competitive Revisions For Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 from Skin and the Oral Cavity for Rapid Acceleration of Diagnostics Radical (RADx-rad)
NATIONAL INSTITUTES OF HEALTH (NIH)
The purpose of this notice is to update the terms and conditions of award for recipients of grant awards issued under the RADx Radical (rad) initiative. This includes specifically all grants that were issued in response to the following Funding Opportunity Announcements (FOAs) and Notices of Special Interest (NOSIs).
This guide notice does not apply to cooperative agreement awards, or awards issued outside of these FOAs and NOSIs.
In addition to the annual Research Performance Progress Report (RPPR), recipients of awards issued in response to the FOAs and NOSIs above are required to submit an interim progress report every six months outlining key milestones that have been met.
Recipients will continue to report information on the competitive revision supplements in the annual RPPR, Section G.1, as directed by the current term of award, and must include updates to the information provided in the interim report (as outlined in the above bullets).
Please direct all grants policy inquiries to:
NIH Office of Policy for Extramural Research Administration
Division of Grants Policy
For questions regarding a specific grant award please contact the Grants Management Specialist identified in the Notice of Award.